Xbrane has engaged life science valuation specialist, Venture Valuation AG, to estimate the future value of Xbrane’s license agreement for Xdivane, its nivolumab biosimilar candidate. Venture Valuation estimated the pre-tax net-present-value for Xbrane at time of launch to approx. SEK4.4bn based on approx. SEK 9.6bn of accumulated profit sharing during the 10 year from launch timeframe of the license, with 30% occurring during the first 4 years. The following high-level assumptions were applied in the valuation (1) provided by Xbrane and 2-5) estimated by Venture Valuation):
About Venture Valuation
Venture Valuation is an independent firm specializing in the valuation of companies, products, and technologies within the global life sciences sector. For over 25 years, the company has supported entrepreneurs, investors, and pharmaceutical companies with valuations, helping them navigate negotiations, licensing deals, investments, fundraising and strategic growth. Venture Valuation is also the provider of the Biotechgate database and the Biotechgate Digital Partnering conference.